Alshnbari, A., & Idris, I. (2022). Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19?–Targeting hyperinflammation. Current Medical Research and Opinion, 38(3), 357-364. https://doi.org/10.1080/03007995.2022.2027141